Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2022-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | https://www.mjima.org/text.php?&id=356 |